Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Research progress on the mechanism underlying the application of mesenchymal stem cells in the treatment of male infertility

Tian X., Zhang J., Tang X., Guo X., Gong Y., Yang F.

Clinical Trial on Chronic Inflammation, published in Front Endocrinol (Lausanne) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Front Endocrinol (Lausanne) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41019344
PMCID
PMC12460148
DOI
10.3389/fendo.2025.1671247

Abstract (original English)

Male infertility has become an increasingly prominent health issue worldwide. This review systematically evaluated the therapeutic application of different types of MSCs in various male infertility models. The therapeutic effects of MSCs are attributed to mechanisms such as in vivo and in vitro differentiation into germ cells, improved antioxidant capacity of testicular tissue, inhibited secretion of inflammatory factors and elevated anti-inflammatory level of testicular tissue, prevention of excessive apoptosis of testicular tissue cells, restoration of the normal secretion of sexual hormone levels in vivo , and regulation of sperm autophagy. Simultaneously, this study also emphasized on the latest progress in the research of MSC-Exos, with the discussion of its potential advantages over traditional MSC therapy. In addition, this review also elucidated challenges in the clinical translation of MSCs, including safety and standardization issues, as well as the necessity of conducting human clinical trials. On these basis, this research proposed corresponding improvement plans, such as developing engineered MSCs products, optimizing delivery methods and exploring combination therapies, which may provide potential reference for the clinical application of MSCs and MSC-Exos on a large scale.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansInfertility, MaleMesenchymal Stem Cell TransplantationCell DifferentiationMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research